Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Second Quarter 2026 Results
Second quarter 2026 results were reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation was followed by a Q&A session.
Press Releases
August 4, 2026
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
July 30, 2026
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
Upcoming Events
2Sep
2026
Jefferies Swiss Healthcare Seminar - Zurich
Conferences
3Sep
2026
Citi’s European Pharma Bus Tour – Paris
Conferences
9Sep
2026
Bernstein’s Annual Pan-European Strategic Decisions Conference – London
Conferences
Dividend (in dollars) per ADR (½ share)
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00